Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | XIAP | P98170 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579267 | 0.74 | CFD (0.41) | LMNAXIAPPOLBCYP2C19CYP2C9 | |
| SCHEMBL8100592 | 0.74 | SMN1; SMN2 (0.53) | LMNAXIAPPOLBCYP2C19CYP2C9 | |
| SCHEMBL8102978 | 0.73 | TSHR (0.61) | CYP2C19CYP2C9CYP3A4CYP1A2ALDH1A1 | |
| SCHEMBL25658103 | 0.71 | KDM4E (0.60) | LMNACYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL4707127 | 0.71 | NOTUM (0.68) | — | |
| SCHEMBL16350248 | 0.71 | NOTUM (0.68) | — | |
| SCHEMBL8100774 | 0.71 | CYP2C19 (0.50) | POLBCYP2C19CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL13621146 | 0.71 | ALDH1A1 (0.74) | LMNAPOLBCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL7419984 | 0.70 | ALDH1A1 (0.70) | LMNACYP2C19CYP2C9CYP3A4ALDH1A1 | |
| SCHEMBL2824813 | 0.70 | NOTUM (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| WO-2009000878-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | KLK7, KLK5, KLKB1 | LMNA 3816/4885XIAP 1319/4885POLB 4716/4885 |
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | LMNA 3816/4885XIAP 1319/4885POLB 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.